Similar articles

• Nirmatrelvir for Nonhospitalized Adults with Covid-19.

  Chen BS, Hung CH, Wei JC. Chen BS, et al. N Engl J Med. 2022 Aug 4;387(5):474. doi: 10.1056/NEJMc2206277. Epub 2022 Jul 20. N Engl J Med. 2022. PMID: 35857647 No abstract available.
• Nirmatrelvir for Nonhospitalized Adults with Covid-19. Reply.

  Hammond J, Bao W, Simón-Campos A. Hammond J, et al. N Engl J Med. 2022 Aug 4;387(5):475-476. doi: 10.1056/NEJMc2206277. Epub 2022 Jul 20. N Engl J Med. 2022. PMID: 35857649 No abstract available.
• [In symptomatic, nonhospitalized unvaccinated adults with mild to moderate COVID-19 at risk for progression to severe disease, does nirmatrelvir/ritonavir decrease the risk of COVID-19-related hospitalization or all-cause mortality while being safe?].

  Lanthier L, Plourde MÉ, Cauchon M. Lanthier L, et al. Rev Med Interne. 2022 Apr;43(4):270-271. doi: 10.1016/j.revmed.2022.02.008. Epub 2022 Feb 28. Rev Med Interne. 2022. PMID: 35279350 Free PMC article. French. No abstract available.
• Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.

  Saravolatz LD, Depcinski S, Sharma M. Saravolatz LD, et al. Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180. Clin Infect Dis. 2023. PMID: 35245942 Free PMC article. Review.
• First-generation oral antivirals against SARS-CoV-2.

  Sendi P, Razonable RR, Nelson SB, Soriano A, Gandhi RT. Sendi P, et al. Clin Microbiol Infect. 2022 Sep;28(9):1230-1235. doi: 10.1016/j.cmi.2022.04.015. Epub 2022 May 8. Clin Microbiol Infect. 2022. PMID: 35545195 Free PMC article. Review.